checkAd
    Startseite > Aktien > Verastem > Nachrichten
    Verastem Aktie
    1,0200
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 01.06.23 Nasdaq
    1,0000
     
    USD
    2.000 STK
    Geldkurs 31.05.23
    1,0100
     
    USD
    23.300 STK
    Briefkurs 31.05.23
    ISIN: US92337C1045 · WKN: A1JTPU · SYM: VSTM · USA

    Neueste Nachrichten

    Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
    18.04.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.04.24 · Business Wire (engl.) · Verastem
    Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
    18.03.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
    14.03.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
    11.03.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
    05.03.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
    05.03.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers
    29.01.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
    18.01.24 · Business Wire (engl.) · Verastem
    Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
    11.01.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    05.01.24 · Business Wire (engl.) · Verastem
    Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
    18.12.23 · Business Wire (engl.) · Verastem